Ignota Labs has harvested more assets for its drug candidate rehabilitation scheme, snapping up Kronos Bio’s clinical pipeline months after a series of setbacks drove the biotech off public markets. U ...
Source: Analyst estimates for the quarter provided by FactSet. Overview of Kronos Worldwide's Business and Key Success Factors Kronos Worldwide is one of the world's top five producers of titanium ...
Kronos is a HOLD: TiO2 demand should rise, but KRO lacks operating leverage and control over key feedstocks to benefit from upside. KRO faces significant competition from Chinese producers, especially ...
Big names returned to the annual National Association of Music Merchants Show in 2025, bringing with them a plethora of musical products from the old school to the futuristic. Companies like Boss, ...
Kronos Bio ends partnership with GenentechKronos Bio, Inc. has terminated its collaboration with Genentech, Inc. and F. Hoffmann-La Roche Ltd, effectively canceling a material definitive agreement ...
Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...
Kronos Q324 sales volumes soared, offsetting flat TiO2 selling prices to deliver +22% YoY revenue growth along with improved profitability. The company faces high growth expectations as it integrates ...
Kronos Worldwide's stock price closed at $10.19. It is down -21.07% in the last 3 months and up 11.73% in the last 12 months. Kronos Worldwide saw 2 positive EPS revisions and 0 negative EPS revisions ...
The effects from vendor UKG’s Kronos Private Cloud timekeeping and payroll software outage in 2021 have echoed far beyond that year for affected organizations. Those settling included UKG itself. Last ...
The projected fair value for Kronos Worldwide is US$11.99 based on Dividend Discount Model Current share price of US$11.73 suggests Kronos Worldwide is potentially trading close to its fair value ...
Kronos Bio has made its second round of layoffs in five months, with another fifth of the biotech’s workforce heading to the exits as the company focuses on a CDK9 inhibitor. Laying off 21% of staff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback